The Arrowhead Pharmaceuticals, Inc. Expected to Earn Q2 2017 Earnings of ($0.16) Per Share (ARWR), Report finds

The Arrowhead Pharmaceuticals, Inc. Expected to Earn Q2 2017 Earnings of ($0.16) Per Share (ARWR), Report finds

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Monday, February 6th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.03. Arrowhead Pharmaceuticals had a negative net margin of 1,663.58% and a negative return on equity of 89.07%. The company earned $4.37 million during the quarter, compared to analyst estimates of $13.24 million.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities researchers at Jefferies Group dropped their Q2 2017 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a research report issued to clients and investors on Monday. Jefferies Group analyst E. Yang now anticipates that the brokerage will post earnings per share of ($0.16) for the quarter, down from their previous estimate of ($0.08). Jefferies Group currently has a “Hold” rating and a $2.00 target price on the stock. Jefferies Group also issued estimates for Arrowhead Pharmaceuticals’ Q3 2017 earnings at ($0.13) EPS, Q4 2017 earnings at ($0.10) EPS, FY2017 earnings at ($0.56) EPS, FY2018 earnings at ($0.44) EPS, FY2019 earnings at ($0.34) EPS and FY2020 earnings at ($0.28) EPS.

A number of other equities research analysts have also issued reports on ARWR. Chardan Capital lowered shares of Arrowhead Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $8.00 to $2.00 in a report on Wednesday, November 30th. Cantor Fitzgerald reissued a “buy” rating and issued a $15.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, November 10th. William Blair lowered shares of Arrowhead Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $12.00 to $2.00 in a report on Wednesday, November 30th. Finally, Piper Jaffray Companies lowered shares of Arrowhead Pharmaceuticals from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $10.00 to $2.00 in a report on Wednesday, November 30th. Five equities research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company. Arrowhead Pharmaceuticals currently has an average rating of “Hold” and an average price target of $2.81.

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) traded up 1.49% during midday trading on Thursday, reaching $2.05. 136,556 shares of the company were exchanged. The firm’s market capitalization is $152.87 million. The firm has a 50-day moving average of $1.80 and a 200 day moving average of $4.69. Arrowhead Pharmaceuticals has a 52 week low of $1.20 and a 52 week high of $8.22.

Several hedge funds have recently added to or reduced their stakes in ARWR. Agran Libbie purchased a new stake in Arrowhead Pharmaceuticals during the third quarter worth $135,000. Bank of Montreal Can raised its position in shares of Arrowhead Pharmaceuticals by 4,355.8% in the third quarter. Bank of Montreal Can now owns 22,502 shares of the company’s stock valued at $166,000 after buying an additional 21,997 shares in the last quarter. Moors & Cabot Inc. raised its position in shares of Arrowhead Pharmaceuticals by 11.0% in the third quarter. Moors & Cabot Inc. now owns 40,270 shares of the company’s stock valued at $292,000 after buying an additional 4,000 shares in the last quarter. Falcon Point Capital LLC raised its position in shares of Arrowhead Pharmaceuticals by 18.8% in the third quarter. Falcon Point Capital LLC now owns 58,398 shares of the company’s stock valued at $339,000 after buying an additional 9,251 shares in the last quarter. Finally, Emerald Acquisition Ltd. bought a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at approximately $390,000. Hedge funds and other institutional investors own 43.11% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

Related posts

Leave a Comment